Skip to content
zameds

Abrocitinib (Cibinqo, Abrocitinib Pfizer)

Abrocitinib

Pfizer Laboratories (Pty) Ltd

Registration

Applicant
Pfizer Laboratories (Pty) Ltd
Registrations
6

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Cibinqo 50 MG

EACH TABLET CONTAINS ABROCITINIB 50,0 mg

50 mg57022657/13.12/0226RegisteredNot determinedNone
Cibinqo 100 MG

EACH TABLET CONTAINS ABROCITINIB 100,0 mg

100 mg57022757/13.12/0227RegisteredNot determinedNone
Cibinqo 200 MG

EACH TABLET CONTAINS ABROCITINIB 200,0 mg

200 mg57022857/13.12/0228RegisteredNot determinedNone
Abrocitinib 50 MG pfizer

EACH TABLET CONTAINS ABROCITINIB 50,0 mg

50 mg570229.22657/13.12/0229.226RegisteredNot determinedNone
Abrocitinib 100 MG pfizer

EACH TABLET CONTAINS ABROCITINIB 100,0 mg

100 mg570230.22757/13.12/0230.227RegisteredNot determinedNone
Abrocitinib 200 MG pfizer

EACH TABLET CONTAINS ABROCITINIB 200,0 mg

200 mg570231.22857/13.12/0231.228RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C14H21N5O2S323.42 g/mol

N-[3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide

Drag to rotate. Structure from PubChem CID 78323835.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles